QC
FBIO icon

Quadrature Capital’s Fortress Biotech FBIO Stock Holding History

Quadrature Capital’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-49,096
Closed -$180K – 1543
2025
Q4 		$180K Buy
+49,096
New +$140K ﹤0.01% 998

Other funds holding FBIO

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Quadrature Capital's FBIO Position: Q1 2026 in Review

Quadrature Capital sold out of Fortress Biotech (FBIO) in Q1 2026, closing a stake of 49,096 shares — an estimated $180K sold.

Quadrature Capital first reported a position in FBIO in Q4 2025 and held it in 1 quarter. The position peaked at $180K in Q4 2025. 51 funds tracked by Wall St. Rank hold FBIO as of Q1 2026.

  • Quadrature Capital reported no remaining Fortress Biotech position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 49,096 Fortress Biotech shares in Q1 2026, an estimated $180K.
  • Quadrature Capital first reported a position in Fortress Biotech in Q4 2025 and held it in 1 quarter.
  • Quadrature Capital's Fortress Biotech position peaked at $180K in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.